RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT(ACAD):
Blade
1) Yes, I was very pleasantly surprised. I don't know whether this is a new trend or just an exception--I hope for the former. Laughren retired this past December. I had the opportunity to talk with him at length a couple weeks ago at a meeting: Very decent and knowledgeable guy. no agenda other than doing the right thing, but rather conservative and narrow in his view of how to get there. It wouldnt take much to be more flexible.
2) I have a good friend whose firm owns a lot of ACAD--He would say it is not yet fully valued, based on the current market cap against likely peak sales of pimavanserin for PD, AD, sz.
3) Back in December I met with a pharma regarding licensing opportunities. Acadia had just released its data and the price had risen, but I told them that it pimavanserin should be a priority target for a partnership. They complained that the price had just gone up. Well, it just got a lot more expensive. And Uli Hacksell is hardly an impulsive CEO, he doesnt have to move quickly. Given that most large pharmas continue to lowball their CNS partnering offers, I'm not expecting imminent news. But then again, someone could decide to wrap this up next week, making Acadia an offer they can't refuse. It would surprise me though.

Congratulations on holding ACAD longterm.

NP